Physician profile
Lisa Scudder
NPI 1447345202
$724.28
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $149.93 | 2019 | |
| Allergan, INC. | $128.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $82.89 | 2019 | |
| Pfizer INC. | $63.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.55 | 2019 | |
| Amgen INC. | $48.38 | 2019 | |
| Abbvie INC. | $36.57 | 2019 | |
| Gilead Sciences, INC. | $31.70 | 2019 | |
| Ibsa Pharma INC. | $16.60 | 2019 | |
| Merck Sharp & Dohme LLC | $13.90 | 2019 | |
| Amarin Pharma, INC. | $12.71 | 2019 | |
| Nevro Corp. | $12.27 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Scudder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.